Skip to content

Study on Abnormal Characteristics of Immunome and Biomarkers of Schizophrenia Based on Clinical Cohort

Study on Abnormal Characteristics of Immunome and Biomarkers of Schizophrenia Based on Clinical Cohort

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200058861
Enrollment
Unknown
Registered
2022-04-18
Start date
2023-01-01
Completion date
Unknown
Last updated
2024-01-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia and psychotic disorders

Interventions

control group:NO
SCZ patient group:Routine treatment

Sponsors

Luxian Lv
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 55 Years

Inclusion criteria

Inclusion criteria: SCZ admission criteria: 1. In the acute stage of the disease, it meets DSM-5 diagnostic criteria, the course of the disease does not exceed 3 years, and the Positive and Negative Syndrome Scale (PANSS) = 60 points; 2. Han nationality, 18-55 years old, BMI of 18.5-23.9kg/m2, and at least one guardian shall monitor the patient within one year; 3. It is estimated that there will be no problems such as relocation of residence, inconvenient transportation, and difficulty in medical treatment during the whole study process; 4. Obtain the informed consent of the patient and guardian, and sign the informed consent form; Inclusion criteria for healthy and normal persons: 1. Be in good health and have no mental illness meeting DSM-5 diagnostic criteria; 2. No family history of mental illness; 3. No serious physical disease; 4. Han nationality, 18-55 years old; 5. There is no statistical difference between the gender, education level and the patient group; 6. Be able to cooperate in completing the evaluation of the project and sign the informed consent form; 7. No contraindication of magnetic resonance imaging (MRI).

Exclusion criteria

Exclusion criteria: Criteria for inclusion and exclusion of SCZ patients: 1. Co morbidity of immune diseases and serious somatic diseases or alcohol abuse; 2. Serious physical disability, unable to complete follow-up; 3. People suffering from other serious mental diseases, mental retardation, dementia and severe cognitive impairment; 4. Currently receiving or preparing to receive other clinical studies; 5. Have definite physical diseases such as hypertension and diabetes; 6. Laboratory examination shows liver and kidney function damage or other serious physical diseases and metabolic disorders; 7. Pregnant women or breast-feeding period. Exclusion criteria for healthy normal people: 1. Have a history of infectious diseases, immune system disease and substance dependence within two weeks; 2. Brain trauma, epilepsy or other organic brain diseases; 3. Have definite physical diseases such as hypertension and diabetes; 4. Laboratory examination shows liver and kidney function damage or other serious physical diseases and metabolic disorders; 5. Pregnant women or breast-feeding period.

Design outcomes

Primary

MeasureTime frame
DSM-5;PNASS;MATRICS Consensus Cognitive Battery;Proteomics assay analysis;Animal behavior evaluation;Detection of inflammatory factors;Neural markers;Genetic testing for schizophrenia;Metabolomics testing;

Secondary

MeasureTime frame
Neuroimaging tests;

Countries

China

Contacts

Public ContactLuxian Lv

The Second Affiliated Hospital of Xinxiang Medical University

llxof2fy@xxmu.edu.cn+86 373 3373969

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026